Fludrocortisone

Limits on what this shows

• Key negative/null findings: The EU-AIR European registry (670 primary adrenal insufficiency patients, 605 on fludrocortisone) found no clear dose-response association between mineralocorticoid dose/body-surface-area and either blood pressure or serum potassium/sodium across the cohort as a whole; this is best read as a treat-to-target confound (fludrocortisone dose is itself titrated against potassium and blood pressure in routine practice, which flattens any simple dose-response relationship) rather than evidence against the underlying mechanism, and it does not contradict either the label or the APECED cohort's direct comparison against untreated controls.
• At-risk subgroups: Higher-dose regimens (above the typical 0.05-0.2 mg/day replacement range), older adults, patients on concurrent diuretics or other potassium-wasting drugs, and patients with reduced oral intake or intercurrent illness. Because primary adrenal insufficiency itself, if inadequately treated, tends toward hyperkalemia (aldosterone deficiency), a hypokalemic direction on fludrocortisone is attributable to the drug rather than to the underlying disease, which argues against simple confounding by indication (Hard Rule 6).
• Counter-evidence: Multiple published case reports describe clinically significant, sometimes hospitalization-requiring hypokalemia attributed to fludrocortisone, including an 85-year-old woman with weakness, cramping, and a fall whose potassium normalized only after fludrocortisone discontinuation and switch to midodrine, and a separate report of severe metabolic alkalosis. The Cochrane systematic review of fludrocortisone for orthostatic hypotension (13 studies, 513 participants, only 28 in randomized trials of 2-3 weeks' duration) rated adverse-event evidence "very low certainty" and described side effects as "minimal" in those short, small trials, but those trials were not designed or powered to detect electrolyte disturbance and are a materially different, shorter-exposure population than the adrenal-insufficiency replacement-therapy cohorts cited above.

Regulatory status

The US label states directly that fludrocortisone "increases the urinary excretion of both potassium and hydrogen ions"; the UK SmPC classifies hypokalemia as a very common adverse effect (MedDRA frequency category) and separately lists hypokalemic alkalosis among fluid/electrolyte reactions requiring monitoring.

Population evidence

A peer-reviewed cohort of 44 Finnish patients with autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED), most with primary adrenal insufficiency on fludrocortisone replacement (median dose 0.1 mg/day, range up to 0.5 mg/day), compared against 68 matched healthy controls over a median 34.3-year follow-up, found the fludrocortisone-treated patients had significantly lower median plasma potassium and higher plasma sodium than controls; 14 of 44 patients (32%) experienced at least one clinically apparent hypokalemic episode, and dose reduction was the standard clinical response.

Mechanism

Fludrocortisone activates the mineralocorticoid receptor in the distal nephron (distal convoluted tubule and collecting duct), upregulating the epithelial sodium channel (ENaC) and basolateral Na-K-ATPase; sodium reabsorption is obligately coupled to potassium (and hydrogen) secretion into the tubular lumen.

Counter-evidence held on record

This is a true renal-wasting/depletion-direction finding, not the drug's therapeutic target (sodium retention is the intended effect; potassium loss is its coupled consequence). Potassium repletion, when indicated, must be lab-guided and prescriber-directed given the cardiac risk of both under- and over-correction; no standing supplement dose is recommended here (see Safety Review).

Limits on what this shows

• What would fill it: A fludrocortisone-specific human cohort or trial directly measuring magnesium, calcium, or vitamin D status against a defined dose or duration boundary, showing a real (not merely theoretical) deficit in a bounded subgroup.

Why empty

Orange requires at least one Tier A source with fludrocortisone in the cohort showing a real, bounded deficit. Magnesium came closest: a Tier A pediatric cohort (Turkish Journal of Medical Sciences, 43 patients) found no hypomagnesemia at standard replacement doses, and the only source showing an actual magnesium deficit is a single Tier B case report at a higher, split-dose regimen confounded by comorbid hypoparathyroidism. Calcium and vitamin D are mentioned only as a general monitoring note in the UK label, without a quantified fludrocortisone-specific deficit study. None of these clears the orange bar; all are graded yellow below.

Limits on what this shows

• Key negative/null findings: The pediatric cohort (Tier A, drug-specific, n=43) is itself the key null finding: no hypomagnesemia and no dose-response signal at doses up to 0.2 mg/day or 390.7 μg/m²/day, directly contradicting a blanket depletion claim at ordinary replacement dosing.
• At-risk subgroups: The one positive case occurred on a higher, split (twice-daily) dosing regimen in a patient with comorbid hypoparathyroidism, which independently predisposes to magnesium and calcium disturbance; this confound is disclosed rather than treated as clean drug-attributable evidence.
• Counter-evidence: The pediatric Tier A cohort's null result at standard doses is the strongest evidence in this entry and caps the grade at yellow rather than orange, since the only positive finding is a single confounded Tier B case report, not a Tier A deficit in a defined bounded subgroup.

Population evidence

"Does fludrocortisone treatment cause hypomagnesemia in children with primary adrenal insufficiency?" (Turkish Journal of Medical Sciences, 2021, PMID 33155789) is a multi-center retrospective cohort of 43 children and adolescents (median age 9.2 years) on fludrocortisone (median 0.1 mg/day, range 0.025-0.2 mg/day, up to 390.7 μg/m²/day in the high-dose subgroup); mean serum magnesium was 2.05 (±0.13) mg/dL, no hypomagnesemia was observed in any patient, and there was no significant difference between standard- and high-dose subgroups (P>0.05). The paper references unspecified adult studies reporting roughly 5% hypomagnesemia incidence, but did not provide a retrievable citation for that figure this session. Separately, a case report (European Congress of Endocrinology 2016 abstracts, EP275) describes a 27-year-old woman with autoimmune polyglandular syndrome type 1 who developed symptomatic hypomagnesemia (serum magnesium 0.53 mmol/L, presenting with abdominal pain and carpopedal spasm) four months after an evening 100 μg dose was added to an existing 200 μg morning dose (300 μg/day total, at the upper end of typical dosing), alongside hypokalemia and hypocalcemia; magnesium improved to 0.72 mmol/L with intravenous replacement.

Mechanism

Aldosterone/mineralocorticoid-receptor activation increases distal-tubule magnesium excretion via TRPM6/TRPM7 channel regulation; the case report's authors additionally propose that fludrocortisone-induced hypokalemia itself impairs the lumen-negative transepithelial voltage gradient that normally drives passive magnesium reabsorption in the thick ascending limb and distal convoluted tubule, linking this entry mechanistically to the Potassium entry above (see Overlap Map).

Counter-evidence held on record

Not supported at standard once-daily replacement dosing; theoretical risk is concentrated at higher or split-dose regimens and in patients with independent magnesium-handling disorders. No supplement dose is recommended here (see Safety Review).

Limits on what this shows

• Key negative/null findings: None identified specific to fludrocortisone; the dose-calibration reasoning above is this dossier's own boundary-setting, not a null study result, and is disclosed as such.
• At-risk subgroups: Patients on fludrocortisone in combination with a separate, higher-dose glucocorticoid (as in congenital adrenal hyperplasia regimens combining fludrocortisone with hydrocortisone or prednisolone), where the calcium/bone risk is more plausibly attributable to the co-administered glucocorticoid than to fludrocortisone itself.
• Counter-evidence: No source located contradicts the label's general monitoring statement; the absence is of confirming, drug-specific deficit data, not of contrary data.

Population evidence

No fludrocortisone-specific human cohort measuring calcium excretion, absorption, or bone mineral density was located despite multi-phrasing searches (PubMed listing pages, Europe PMC before rate-limiting, general web search). The evidence is limited to the UK SmPC's own monitoring language and the general glucocorticoid-class literature (StatPearls, NBK554612) describing measurable bone mineral density loss at prednisone-equivalent doses as low as 5 mg/day.

Mechanism

Fludrocortisone retains meaningful glucocorticoid-receptor affinity (roughly 10-15 times hydrocortisone's potency per milligram) despite its primary use as a mineralocorticoid; at a typical 0.1 mg/day replacement dose this equates to only about 1-1.5 mg of hydrocortisone-equivalent glucocorticoid activity, well below the prednisone-equivalent threshold (roughly 5-7.5 mg/day) associated with measurable bone loss in the class-level literature. The mechanism is therefore present in principle (impaired intestinal calcium absorption, increased renal calcium excretion) but its magnitude at ordinary replacement dosing is not established.

Counter-evidence held on record

Shares its underlying source (the UK SmPC's combined calcium/vitamin D monitoring statement) with the Vitamin D entry below; see Overlap Map. No supplement dose is recommended here (see Safety Review).

Limits on what this shows

• Key negative/null findings: None identified specific to fludrocortisone.
• At-risk subgroups: Same as Calcium: patients on combined fludrocortisone plus higher-dose glucocorticoid regimens (for example congenital adrenal hyperplasia).
• Counter-evidence: None found contradicting the label's monitoring note; the gap is in confirming deficit data, not contrary data.

Population evidence

No fludrocortisone-specific human cohort measuring 25-hydroxyvitamin D was located. The evidence is the UK SmPC's monitoring language itself (Tier A, drug-specific label, but a precautionary statement rather than a reported deficit) plus general corticosteroid-class literature that pairs vitamin D monitoring with calcium/bone risk without isolating vitamin D as an independently depleted nutrient.

Mechanism

Not a direct vitamin D metabolism effect in any source located; the label's pairing of vitamin D monitoring with calcium excretion suggests it is intended as a corrective/supportive measure for the calcium-handling effect above, rather than evidence that fludrocortisone itself lowers circulating vitamin D. See the Calcium entry for the same dose-calibration reasoning (fludrocortisone's glucocorticoid burden at replacement dosing is well below thresholds associated with bone effects in the wider corticosteroid literature).

Counter-evidence held on record

Shares its underlying source (the UK SmPC's combined calcium/vitamin D monitoring statement) with the Calcium entry above; see Overlap Map. No supplement dose is recommended here (see Safety Review).

Limits on what this shows

• Key negative/null findings: None identified for fludrocortisone; not tested at this drug's dose range in any source located.
• At-risk subgroups: Not established for fludrocortisone; if the mechanism applies, it would be expected to require a materially higher glucocorticoid dose than typical fludrocortisone replacement provides.
• Counter-evidence: Cohort test fails for fludrocortisone (prednisone administered, not fludrocortisone), at doses producing a glucocorticoid burden far exceeding fludrocortisone's typical hydrocortisone-equivalent exposure at replacement dosing. Tier B/C class extrapolation, capped at yellow.

Population evidence

"Effect of prednisone on growth and zinc metabolism in rats" (Pediatric Research, 1984) gave weanling rats prednisone at 0.5, 2.0, or 8.0 mg/kg/day for five weeks with a 65-zinc radiotracer study in week five. Whole-body zinc retention fell in a dose-dependent manner (controls retained 90% at 24 hours and 60% at 216 hours, versus 60% and 10% in the highest-dose group), prednisone depressed liver, kidney, muscle, bone, and testicular zinc uptake, and urinary zinc and nitrogen excretion rose with dose. This is a general corticosteroid-class claim also appearing on consumer drug-nutrient depletion guides, which name prednisone, dexamethasone, methylprednisolone, betamethasone, cortisone, and hydrocortisone, never fludrocortisone.

Mechanism

Glucocorticoid-driven catabolic state increases urinary nitrogen and zinc loss as protein turnover accelerates; plausible in principle for any glucocorticoid-receptor agonist, including fludrocortisone's weak glucocorticoid activity, but not demonstrated at fludrocortisone-equivalent low-dose exposure.

Counter-evidence held on record

No fludrocortisone-specific zinc study was located despite multi-phrasing searches; rests entirely on high-dose prednisone rat data, not fludrocortisone-confirmed evidence. No supplement dose is recommended here (see Safety Review).

Limits on what this shows

• Key negative/null findings: None identified for fludrocortisone specifically; fludrocortisone is not associated with clinically significant hyperglycemia in the label or literature reviewed, which weakens rather than strengthens the case for this mechanism applying at replacement dosing.
• At-risk subgroups: Not established for fludrocortisone; if relevant at all, would apply only to unusually high-dose fludrocortisone exposure or co-administration with a separate diabetogenic glucocorticoid.
• Counter-evidence: Cohort test fails for fludrocortisone (the corticosteroid(s) studied in the Ravina trial are not specified as fludrocortisone and were used at anti-inflammatory/immunosuppressive doses); Tier C class extrapolation, capped at yellow, and weaker than the other yellow entries in this dossier given fludrocortisone's minimal diabetogenic activity at replacement dosing.

Population evidence

"Reversal of corticosteroid-induced diabetes mellitus with supplemental chromium" (Ravina et al, Diabetic Medicine, 1999) is the primary source underlying this class-level claim, which also appears on generic consumer corticosteroid-depletion guides (naming prednisone-class drugs, never fludrocortisone) alongside a general literature on urinary chromium loss tracking insulin resistance and hyperglycemia.

Mechanism

Glucocorticoid-induced insulin resistance and hyperglycemia are associated with increased urinary chromium excretion in the general chromium-insulin literature; this requires a diabetogenic glucocorticoid exposure, which fludrocortisone's weak glucocorticoid-receptor activity at 0.05-0.2 mg/day replacement dosing (roughly 1-3 mg hydrocortisone-equivalent) is not established to produce.

Counter-evidence held on record

Weak, dose-mismatched class extrapolation; no supplement dose is recommended here (see Safety Review).